Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New immunotherapy drug BPT567 tested in advanced cancers

NCT ID NCT06779851

First seen Oct 31, 2025 · Last updated May 23, 2026 · Updated 31 times

Summary

This early-phase study tested a new drug called BPT567 in 20 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. The study was terminated early, so final results are not available.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Carolina BioOncology Institute

    Huntersville, North Carolina, 28078, United States

  • Hackensack Meridian John Theurer Cancer Center

    Hackensack, New Jersey, 07601, United States

  • Honor Health Research Institute

    Scottsdale, Arizona, 85260, United States

  • Providence Cancer Institute

    Portland, Oregon, 97213, United States

  • South Texas Accelerated Research Therapeutics (START)

    San Antonio, Texas, 78229, United States

  • Start Midwest

    Grand Rapids, Michigan, 49546, United States

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania, 15232, United States

Conditions

Explore the condition pages connected to this study.